Abstract
Tissue plasminogen activator (t-PA) has restrict therapeutic window for ischemic stroke and hemorrhagic transformation (HT) is the major complications. High mobility group box protein 1 (HMGB1) and MMPs are critical targets for reducing HT. Glycyrrhizin is an antioxidant isolated from Glycyrrhiza glabr a. We hypothesize that glycyrrhizin could inhibit HMGB1, MMPs, reduce HT and improve survival rates in ischemic stroke with delayed t-PA tretament. Male SD rats were subjected middle cerebral artery occlusion (MCAO) for 5 hours plus 19 hours of reperfusion. T-PA (10 mg/kg) was intravenously administrated at 4.5 hours after MCAO and continuously injected for 30 min. Glycyrrhizin (30 mg/kg) was administrated at onset of t-PA treatment and saline was used as control. Major discoveries are as below: (1) Delayed t-PA treatment had increased mortality rate, brain swelling, hemorrhagic transformation with the increase of HMGB1 and MMP-9 expression. (2) Glycyrrhizin significantly inhibited HMGB1 and MMP-9, attenuated HT, decreased mortality and improved neurological outcomes. In conclusion, glycyrrhizin could be an adjuvant therapy with t-PA to improve the therapeutic outcome for ischemic stroke.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.